Insider Transaction Report for David Scadden

This filing details insider transactions by David Scadden, a director at Agios Pharmaceuticals, Inc. On June 18, 2026, Scadden acquired 2,816 shares of common stock through the settlement of restricted stock units (RSUs). The RSUs were granted on June 18, 2025, and vested on June 18, 2026, with shares to be delivered post-vesting. Additionally, on the same date, Scadden was granted new RSUs representing 2,927 shares of common stock, vesting on June 18, 2027. The RSU terms are detailed in footnotes F1, F2, and F3. Scadden also acquired options to purchase 14,950 shares of common stock, granted on June 18, 2026, with vesting on June 18, 2027, as per footnote F4. The transactions reported are marked as non-derivative acquisitions (Code M for stock and A for RSUs and options) and derivative disposals (Code D for RSUs). All transactions were direct holdings.